Zentek Ltd. (ZTEK): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at a company right at the inflection point, and honestly, understanding the new marketing playbook is key to seeing where the next dollar comes from for Zentek Ltd. This firm is making a hard pivot from pure science projects to selling real products, like their ZenGUARD™ coating and new graphite tech, which is a huge shift from their R&D days. We need to look past the massive 2,663.8% year-over-year revenue jump to $605.9 thousand in FY2025, because the Q4 net loss of $-1.84 million shows they are still deep in the investment phase, especially after that $30 million At-The-Market offering back in March. So, let's break down their Product, Place, Promotion, and Price strategy-the four P's-to see if this commercialization push, with the stock trading around $0.75, is built to last.

Zentek Ltd. (ZTEK) - Marketing Mix: Product

The product element for Zentek Ltd. (ZTEK) centers on advanced material science, primarily leveraging nanotechnology for health, safety, and industrial applications. The company's portfolio is built around patented technologies, with a strong current commercial emphasis on its antimicrobial coating and its high-purity graphite assets.

The flagship offering remains the ZenGUARD™ antimicrobial coating. This technology is applied to physical goods, specifically surgical masks and HVAC filters. Shelf-life efficacy testing completed on March 12, 2025, showed that the Viral Filtration Efficiency (VFE) was unchanged after the ZenGUARD™ Enhanced Air Filters were aged for 20 months, confirming consistent performance over time. For surgical masks, production data shows 340,000 masks were manufactured in February 2025, with approximately 100,000 masks in storage at VMedCare as of September 30, 2025. The overall TTM revenue ending September 30, 2025, was reported at $653.80k.

A significant new physical product was announced in November 2025: the Graphite Gel-Based Fire-Retardant (GBFR) product, which Altek Advanced Materials Inc. will commercialize in the US as GraphGel™. This material combines gel properties with expandable graphite to form thermal barriers. Testing showed the coating can be applied at rates exceeding 75 liters per minute (lpm), allowing coverage of an average-sized home in under 30 minutes. Independent ASTM E84 testing on coated Oriented Strand Board (OSB) achieved a Class A fire rating, with a Flame Spread Index (FSI) of 25 for low loading and an FSI of 5 for high loading. Zentek receives a 5% royalty on net sales from Altek for this product.

The Albany Graphite subsidiary has advanced its core material offering toward high-specification markets. The Albany graphite has achieved ultra-high 5N+ purity level (99.9992 wt. % C), confirmed in October 2025 testing. This purity level resulted in a calculated Equivalent Boron Concentration (EBC) of 2.60 ppm, which is below the 3 ppm specification required for nuclear applications. Earlier in 2025, a proof-of-concept purification of a sample with 85% Total Graphitic Carbon (TGC) yielded 99.9991% purity using an electrothermal FBR. The subsidiary was awarded a $500,000 Critical Minerals Innovation Fund (CMIF) grant for purification and development work.

Zentek Ltd. maintains a core focus on advanced polymer and coating technologies, specifically for thermal management applications, such as phase-change materials and flexible polymer foams tailored for battery and power electronics in electric vehicles. The company also continues development on its aptamer-based platform technology for diagnostics and therapeutics, with Triera Biosciences Ltd. owning the exclusive, global licensing rights for this technology.

The following table summarizes key quantitative product specifications and recent financial context:

The company's product development efforts are supported by specific performance metrics achieved in testing, such as:

• - ZenGUARD™ coating maintaining performance over 20 months.
• - GBFR protecting surfaces exposed to 1500°C for two minutes.
• - Albany Graphite achieving EBC of 2.60 ppm.
• - Albany Graphite initial purification yielding 99.9991% purity from 85% TGC concentrate.

Zentek Ltd. (ZTEK) - Marketing Mix: Place

The Place strategy for Zentek Ltd. (ZTEK) centers on a centralized production model feeding a network of specialized B2B commercial partners and strategic alliances for market access.

ZenGUARD™ production is centralized at the facility in Guelph, Ontario. The company operates its Manufacturing Centre in Guelph, Ontario, which is 25,680 square feet of industrial zoning space. This facility has an estimated capacity to produce ZenGUARD™ coating for the equivalent of 720 million masks per month. The laboratory and R&D facility is a separate 4,300 square foot space also located in Guelph, Ontario.

Distribution relies on B2B commercial partners and strategic alliances, not direct-to-consumer sales. The entire distribution model is structured around leveraging established commercial channels rather than direct sales to end-users.

U.S. market entry for surgical masks is secured through the Medwell Solutions LLC distribution agreement. This definitive distribution agreement with Dallas, Texas-based Medwell Solutions LLC for ZenGUARD™ Enhanced Surgical Masks in the U.S. was signed on March 18, 2024. The agreement is structured for a period of two years following the date of facility establishment registration and issuance of market clearance from the U.S. Food and Drug Administration.

The distribution network is detailed below, showing the scope of key partnerships as of late 2025:

Global expansion efforts are actively fostering partnerships in India, Middle East, and South America. The Middle East strategy includes the MOU with Al-Ramez International Group, which outlines developing a world-class graphene production facility in the KSA. Furthermore, the agency agreement with RSK Environment Ltd., headquartered in the UK, is designed to support international growth by identifying sales opportunities in key global markets, including the Gulf Cooperation Council (GCC) region.

Operating footprint includes North America, Europe, and Asia for collaboration with partners. The North American footprint is anchored by the Guelph, Ontario production site and the Medwell distribution in the U.S. The European and Asian reach is being developed through the agency agreement with RSK Environment Ltd., which facilitates promotion in over 20 countries. The company is also actively working with partners to advance commercialization in India and South America, as noted in their corporate updates.

• ZenGUARD™ production facility size: 25,680 square feet.
• Estimated monthly mask coating capacity: 720 million.
• U.S. distribution agreement term: Two years post-clearance.
• RSK agency agreement reach: More than 20 countries.
• RSK agency agreement term: Three years.

Zentek Ltd. (ZTEK) - Marketing Mix: Promotion

The promotional activities for Zentek Ltd. (ZTEK) in late 2025 reflect a distinct shift in corporate narrative, moving from pure research and development focus toward aggressive commercialization, a transition solidified by the appointment of Mohammed Jiwan as Chief Executive Officer on November 25, 2025.

The core marketing message centers on the ZenGUARD™ value proposition, consistently framed around making partner products better, safer, and greener. This science-backed approach is critical for targeting commercial partners, specifically Original Equipment Manufacturers (OEMs) and healthcare systems.

Public relations efforts heavily emphasize validated Intellectual Property (IP) milestones and positive third-party testing results. For instance, the Albany Graphite Corp. subsidiary's work on nuclear suitability is a key narrative point. Testing confirmed that Albany graphite achieved an Equivalent Boron Concentration (EBC) of 2.60 ppm, successfully meeting the nuclear industry specification of less than 3 ppm, with purity reaching 99.9992 wt. % C (5N+) as of October 6, 2025.

Promotional activities also include direct engagement with potential customers through product performance metrics. ZenGUARD™ Enhanced Air Filters demonstrated an average infectious aerosol removal efficiency of MS2 bacteriophage of 42%, compared to an untreated filter's 16%, based on results announced June 12, 2025. Furthermore, shelf-life efficacy testing on aged ZenGUARD™ Enhanced Air Filters, aged for 20 months, was completed on March 12, 2025, supporting claims of long-term reliability.

Capital market promotion is a significant component, designed to fund commercial scale-up. Zentek Ltd. announced entering into an At-The-Market (ATM) offering agreement on March 3, 2025, to raise aggregate gross proceeds of up to US$30 million through the sale of Common Shares on the Nasdaq Capital Market, with Rodman & Renshaw LLC acting as the exclusive sales agent.

The promotional focus on commercial readiness is supported by tangible production and distribution updates:

• 340,000 ZenGUARD™-coated surgical masks manufactured in February 2025.
• Approximately 100,000 ZenGUARD™-coated surgical masks in storage at VMedCare as of September 30, 2025.
• The new Graphite Gel-Based Fire-Retardant (GBFR) product achieved Technology Readiness Level (TRL) 5 as of November 5, 2025.

Here's a quick look at key promotional data points as of late 2025:

The company's market capitalization stood at US$81.5m recently, providing context for the capital market promotional efforts.

Zentek Ltd. (ZTEK) - Marketing Mix: Price

You're looking at the pricing side of Zentek Ltd. (ZTEK) as we close out 2025. This isn't about setting a sticker price for a consumer good; it's about the structure of commercial agreements, which is key when your model is strictly B2B.

The pricing model is fundamentally B2B, which means the actual amounts customers pay are likely derived from a combination of technology access and volume. We're talking about structuring revenue through licensing fees and material supply contracts for their nanotechnology-enabled solutions.

Here's a look at the financial backdrop influencing these pricing decisions, showing the massive top-line acceleration against ongoing investment costs:

The company is clearly still in a high-growth investment phase, which dictates that pricing strategies must balance capturing value from early adopters with the need to secure volume for scale. The Q4 2025 net loss of $-1.84 million shows the burn rate associated with this expansion, which management is funding, in part, through planned capital expenditure of around $500,000 for production expansion.

Financing options and credit terms in a B2B context are critical for accessibility, especially when dealing with large, multi-year contracts that might be necessary to justify the R&D spend. The market's view on this strategy is reflected in the stock performance. As of December 2025, the stock price is trading around $0.75. This level is notable because it is below the Nasdaq minimum bid requirement, which is a factor that affects investor confidence and, indirectly, the perceived risk premium applied to any long-term pricing agreements Zentek Ltd. negotiates.

To summarize the key financial markers related to pricing strategy:

• Pricing model is B2B, focused on licensing and supply contracts.
• Fiscal Year 2025 revenue reached $605.9 thousand, representing 2,663.8% Y/Y growth.
• The company reported a Q4 2025 net loss of $-1.84 million.
• Anticipated capital expenditure for expansion is approximately $500,000.
• Stock price as of late 2025 is near $0.75, below the Nasdaq minimum bid.

Finance: draft 13-week cash view by Friday.